Investment Thesis
Caris Life Sciences demonstrates exceptional 97% revenue growth with positive free cash flow generation ($22.5M) and a substantial cash balance ($819.9M), indicating strong market demand and financial runway. However, the company remains unprofitable at the net income level with concerning 0.4x interest coverage, requiring successful execution to achieve profitability and debt management.
Strengths
- Exceptional 97% YoY revenue growth in medical laboratory services sector
- Positive free cash flow of $22.5M with 10.4% FCF margin indicates cash generation capability
- Strong liquidity position with $819.9M cash and 7.05x current ratio provides significant financial flexibility
- Net loss improving 87.3% YoY suggests trajectory toward profitability
- Operating cash flow positive at $32.9M despite growth-stage operations
Risks
- Company remains unprofitable on net income basis (-$510K) with negative net margin of -0.2%
- Critical weakness: 0.4x interest coverage ratio indicates inability to comfortably service debt from operations
- Thin 2.4% operating margin requires continued revenue growth and margin expansion for sustainability
- High long-term debt of $381.1M represents 64% of equity, constraining financial flexibility
- Gross profit data unavailable; inability to assess service delivery margin quality and pricing power
Key Metrics to Watch
- Path to net profitability and sustained positive net income
- Interest coverage ratio improvement toward 1.5x+ to ensure debt service comfort
- Gross margin trend as company scales (need for transparency on cost structure)
- Operating margin expansion toward industry benchmarks
- Free cash flow sustainability and conversion rate of revenue growth to cash generation
Financial Metrics
Revenue
216.2M
Net Income
-510.0K
EPS (Diluted)
$0.00
Free Cash Flow
22.5M
Total Assets
1.2B
Cash
819.9M
Profitability Ratios
Gross Margin
N/A
Operating Margin
2.4%
Net Margin
-0.2%
ROE
-0.1%
ROA
0.0%
FCF Margin
10.4%
Balance Sheet & Liquidity
Current Ratio
7.05x
Quick Ratio
7.05x
Debt/Equity
0.64x
Debt/Assets
48.9%
Interest Coverage
0.41x
Long-term Debt
381.1M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-09T09:50:34.608702 |
Data as of: 2026-03-31 |
Powered by Claude AI